Asthma
EU ASTHMA PARTNER
US ASTHMA PARTNER
EU Partner
An Introduction to Asthma
Asthma is a common and potentially life-threatening chronic inflammatory airway disease. Despite many therapeutic advances, it remains underdiagnosed and undertreated. The mainstay of therapy is maintenance controller therapy such as inhaled corticosteroids, together with separate short-acting β2-agonists for acute symptom relief, but treatment adherence is a major challenge. The heterogeneity of asthma makes it difficult to identify specific therapeutic targets. For patients with specific subtypes of severe asthma, such as eosinophilic asthma, targeted therapies including omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab, can reduce exacerbation rates and improve disease control. As experience with biological therapies increases, they are expected to play a more prominent role in treatment strategies, and novel therapeutic targets such as semaphorins and RhoA/Rho‐kinase, are being investigated.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
The current treatment landscape for severe asthma faces major challenges despite biologic advances targeting type 2 inflammation. Current biomarkers like BEC and FeNO inadequately predict treatment response. To optimize precision medicine, improved molecular phenotyping and novel non-invasive biomarkers are urgently needed to better identify asthma endotypes and guide therapy.
Asthma affects nearly 300 million people worldwide.1 Despite a notable decline in age-standardized prevalence, mortality and disability-adjusted life years over the past three decades, the burden of asthma remains high in many countries including low-middle-income countries.2 Climate change is also predicted ...
We are excited to welcome you to San Francisco for the ATS 2025 International Conference! Leaders, as well as emerging scientists and clinicians, who are at the forefront of medical breakthroughs and clinical innovation in pulmonary, critical care and sleep medicine will gather for networking and inspiring talks.
GSK has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application for depemokimab, an investigational monoclonal antibody targeting interleukin-5 (IL-5), for two indications: as an add-on maintenance treatment for asthma in patients aged 12 and older with type 2 inflammation characterized by an eosinophilic phenotype, and as an add-on treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
As 2024 draws to a close, we’re celebrating a fantastic year of content.
A recent phase 2 trial published in The Lancet Respiratory Medicine has demonstrated that benralizumab, a monoclonal antibody targeting interleukin-5 receptor-α, can significantly reduce treatment failure in eosinophilic exacerbations of asthma and COPD.
The International Primary Care Respiratory Group (IPCRG), is proud to host the 8th IPCRG Scientific Meeting in Brașov, Romania, on Friday 11 and Saturday 12 April 2025. This event, in partnership with the RespiRO team and the Transilvania University of Brașov promises to bring together researchers, innovators, and industry leaders to advance respiratory care in primary health settings.
The International Primary Care Respiratory Group (IPCRG) has initiated a global social movement to bring meaningful change in asthma management. The driving idea behind this initiative is a recognition that, while the current approach may feel sufficient to many, it falls short of optimal care. The IPCRG network sees clear evidence of avoidable harm and unnecessary costs in the current asthma management framework, which continue to impact lives and wellbeing.1 To counteract this, IPCRG's "Asthma Right Care" aims to inspire a shift towards better care practices by reducing both overuse and underuse of effective treatments. This means moving beyond episodic symptom relief and acute responses to establish a chronic care model that adheres to international or national asthma guidelines, prioritizing the appropriate use of anti-inflammatory inhaled medications.
A new European Respiratory Society (ERS) statement on preschool wheezing disorders represents a significant update in the approach to diagnosing and managing this complex condition in young children.
As we observe World Lung Day, it is crucial to reflect on the escalating impact of respiratory diseases across the globe. Chronic respiratory diseases — including chronic obstructive pulmonary disease (COPD), asthma, lung cancer, pulmonary hypertension, obstructive sleep apnea, and others — continue to rank among the leading causes of morbidity and mortality worldwide. The World Health Organization’s latest data underscores the persistence of the global respiratory crisis:
The Global Initiative for Asthma (GINA) has released its 2024 update on asthma management and prevention. This report, authored by the GINA Science Committee, brings significant updates on various topics crucial for effective asthma management.
Welcome to the latest edition of touchREVIEWS in Respiratory & Pulmonary Diseases. As we continually strive to deliver cutting-edge research and insightful commentary, this issue is no exception, featuring a diverse array of articles that illuminate both emerging treatments and ...
The topic of the carbon footprint of human activities is one frequently discussed worldwide. There have been conscious efforts across multiple fields, including healthcare, to reduce their carbon footprint. In Canada, 4.6% of greenhouse gases (GHG) are manufactured by the healthcare ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
